Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024Marine Maurel, Neus Latorre‐Margalef, Gergő Túri et al.|Eurosurveillance|2024Cited by 50
Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, SpainClara Mazagatos, Jacobo Mendioroz, Mercedes Rumayor et al.|Influenza and Other Respiratory Viruses|2024Cited by 25
Severity of respiratory syncytial virus compared with SARS-CoV-2 and influenza among hospitalised adults ≥65 yearsLorena Vega-Piris, Susana Monge, José Luis Mayordomo et al.|Journal of Infection|2024Cited by 17
Effectiveness of influenza vaccination during pregnancy to prevent severe infection in children under 6 months of age, Spain, 2017–2019Clara Mazagatos, Pilar Gallego, Pere Godoy et al.|Vaccine|2020Cited by 16
COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older EuropeansCharlotte Lanièce Delaunay, Carla López Causapé, Clara Mazagatos et al.|JAMA Network Open|2024Cited by 10